Advent Life Sciences logo

Advent Life Sciences

Latest fund size

$178.4M

Announced

October 5, 2026

Global HQ

United Kingdom

Members only

Check size

$2M-$10M

Members only

Stage focus

Seed, Series A, Series B Growth (Series C+)

Members only

Regions of investment

United Kingdom, Europe, United States

Members only

About

Advent Life Sciences is a London-based venture capital firm founded in 2000 that invests in life sciences businesses across the UK, continental Europe, and the United States. The firm backs new drug discovery, enabling technologies, and medical technology companies from early-stage development through growth and commercialization, with additional offices in Paris and Boston.

Contact info

Website

‍

Shahzad Malik - General Partner

shahzad.malik@adventls.com

‍

Don Drakeman - Venture Partner

don.drakeman@adventls.com

‍

Kaasim Mahmood - General Partner

kaasim.mahmood@adventls.com

‍

Dominic Schmidt - General Partner

Satish Jindal - General Partner

‍

Katrine Bosley - Venture Partner

katrine.bosley@adventls.com

Members only

Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.

Investment focus

Advent Life Sciences invests in companies developing new medicines, medical technologies, and enabling platforms, backing businesses from early-stage drug discovery through growth-stage clinical development and commercial scale-up.

The firm's current strategy spans two complementary vehicles: an early-stage fund targeting companies addressing major unmet clinical needs, and a growth fund focused on UK companies advancing through clinical development or scaling commercial operations for non-therapeutic assets.

‍

Members only

What the fund looks for in founders and which sectors it backs.

Fund

British Business Bank agreed to commit up to $178.4 million across two new Advent Life Sciences funds: Advent Life Sciences Fund IV, which received a $79.3 million and $99.1 million commitment for mid-to-late stage companies. Total sizes for both funds have not been publicly disclosed.

The commitments build on British Business Bank's existing relationship with Advent, including its earlier backing of Advent Life Sciences Fund III, and bring the Bank's total commitments across 17 life sciences vehicles to more than $985.0 million, helping attract over $3.96 billion in private-sector capital to the UK life sciences sector.

Advent previously raised $192.4 million for its second fund in 2014, after an earlier $99.1 million fund cornerstoned by the UK Future Technologies Fund's $19.8 million investment in 2010.

Members only

Fund size, LPs and track record.

Other information

Leadership

Advent Life Sciences is led by a team of General Partners: Shahzad Malik, Raj Parekh, Kaasim Mahmood, Dominic Schmidt, and Satish Jindal.

The firm's investment team includes 18 professionals across its London, Paris, and Boston offices.

‍

Investment Strategy

The firm backs life sciences companies from early-stage drug discovery through growth-stage clinical development and commercial scale-up, drawing on a team with scientific, medical, and operational backgrounds.

‍

Notable Investments

Advent's portfolio includes:

  • Proximie
  • Cyted Health
  • Acutus Medical
  • Biocartis
  • F2G
  • NeRRe Therapeutics
  • uniQure

‍

Notable Exits

Advent's realizations include:

  • Algeta (acquired by Bayer)
  • Avila Therapeutics
  • EUSA Pharma
  • Micromet

‍

Members only

Leadership, investment strategy, notable investments and exits.

Unlock this fund's full profile

✓ Emails and LinkedIn for the team

✓ Check size, stage focus and regions of investment

✓ LPs, notable investments and exits

✓ Search and filters across 700+ funds

Unlock this fund and 700+ more

From $14/month, billed yearly. Cancel any time.

Read the newsletter that top VCs and founders keep in their inbox.

Join the weekly newsletter